
Conference Coverage
Latest News

FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3

ASRA Case Highlights When to Reassess Cannabis Use for Chronic Pain

From Awareness to Action: Pharmacists Advancing Antibiotic Stewardship

Galinpepimut-S Cuts Risk of Death by 41% in Phase 3 REGAL Trial

Continuous Glucose Monitoring for Patient Empowerment and Medication Optimization

Shorts










Continuing Education
All News

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.

Adrabetadex cut the risk of death by 55%, but its boxed warning for permanent hearing loss means patients need regular hearing tests.

A once-nightly drop already used to reverse pupil dilation gains a near-vision indication.

PAHO confirmed endemic measles transmission in the US, Mexico, and Bolivia, putting pharmacists' role in vaccination and case detection in focus.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.

A new US DOL rule will require PBMs to disclose their compensation to large self-insured employer plans starting in 2027.

Salia Farrokh, PharmD, MBA, describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica
The FDA approved secukinumab for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering, supported by improved sustained remission and reduced steroid exposure in REPLENISH.

Preserving patient access requires attention to the people, workflows, and financial structures behind the pharmacy counter, not just the number of open pharmacy locations.

The breakthrough is not only in cell and gene therapies but also in whether health care can translate them into practice.

A clear and workable medication plan is an essential part of the transition home.

The FDA's decision comes weeks ahead of giredestrant's scheduled approval date.

Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.

Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss
Peer Reviewed
This case series describes 2 instances of cutaneous sensory disturbance during semaglutide therapy in patients without diabetes and discusses possible mechanisms as hypotheses requiring further investigation.

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

The pertuzumab biosimilar is set to be commercially available in the third quarter of 2028.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.



































